An entire class of proteins called transcription factors has largely been ignored by the pharmaceutical industry because it’s difficult to design and screen drugs against them. But a new study suggests that a key group of transcription factors are in fact ‘druggable,’ including several that could be targeted to treat cancer, metabolic disease, or autoimmune conditions.